* PX'THERAPEUTICS *
2000 - Rhône-Alpes
Grenoble
www.px-therapeutics.com Contract; Research
(also, Contract, Manufacturing)
Key words: Recombinant protein engineering
Mission: to develop biotherapeutics (valuable recombinant proteins) from early stage research up to cGMP production through its specialized technology and manufacturing platforms Protein'eXpert, PX'Monoclonals and PX'Pharma, for third parties
Clients: Pharmaceutical industry, Biotechs
marketing@px-therapeutics.com
Age: 11 year(s)
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS |
|---|
| Personal venture |
Managing Dir.-CEO: Rousselle (Tristan) [co-founder, born 1970, Ph.D. cellular biology]
Sc.Dir.-CSO: Mouz (Nicolas) [co-founder, born 1966, Ph.D. molecular biology]
Prod.Dir.-CTO: Mouz (Sebastien) [Ph.D.]
Fin.Dir.-CFO:
BusDev: Untereiner (Claire)
Financers (Hist.): Vizille Capita (and others), privately owned (registered capital 2007= 0.13 M€) | Turnover (M€) : 3.28 (2009), 2.62 (2008), 2.8 (2007)
Total funding (M€) : n.a.
Last funding (M€) : 1.3
Focus : Multiple
Position : Trade
Company confirm : none |
History | DATE | MILESTONE | TYPE | TIME |
|---|
| 2010 .12 | Production : new additional biomanufacturing unit, dedicated to mammalian cell culture production (opening facility) | INDUS | [10 years] |
| 2010 .08 | Set-up of new subsidiary Promise Advanced Proteomics, offering unique protein Absolute Quantification services | ORGC | [9 years] |
| 2009 .11 | Production : new additional biomanufacturing unit, dedicated to the production of therapeutic proteins and monoclonal antibodies in mammalian cells, in Grenoble (10th anniversary) | INDUS | [9 years] |
| 2008 .10 | Partnering manufacturing agreement with Alizé Pharma on a recombinant L-asparaginase | INDUS | [7 years] |
| 2008 .09 | Company name change from ProteineXpert to PX'Therapeutics, in order to highlight its focus on integrated biotherapeutics development and to avoid labeling confusions | INFO | [7 years] |
| 2008 .07 | Partnering co-commercialization agreement with Althea Technologies (San Diego, USA) | MKTG | [7 years] |
| 2007 .07 | Set-up of PX'Monoclonals subsidiary in Lyon, dedicated to the development of murine and humanized monoclonal antibodies for research and therapeutic purposes | ORGC | [6 years] |
| 2004 .09 | Set-up of PX'Pharma subsidiary to provide with cGMP clinical manufacturing services | ORGC | [3 years] |
| 2003 .11 | Round-financing : 1.3 M€, by undisclosed regional investors | RFIN | [3 years] |
| 2000 .11 | Company founded by Tristan Rousselle and Nicolas Mouz | ORGF | [0 year] | Actualisation / Updating: 22-Sep-2011 |
|
